Healthcare Triangle (HCTI) Financials

Healthcare Triangle’s Q2 2026 results show a significant revenue recovery, but profitability and cash generation remain weak. Revenue reached $9.2 million, up from $3.6 million in the restated Q2 2025, although it declined 6.7% sequentially from $9.9 million in Q1 2026. Revenue remains below the $11.3 million reported in Q4 2022 and $12.0 million in Q3 2022, indicating that the longer-term recovery is still incomplete.

• Revenue rebounded sharply year over year. Q2 2026 revenue increased approximately 158% from the restated Q2 2025 level of $3.6 million. This suggests that recent acquisitions or business initiatives may be expanding the company’s revenue base.
• Gross margin improved from the prior year. Gross profit rose to $2.1 million in Q2 2026 from $494,000 in Q2 2025. Gross margin improved to approximately 22.5%, compared with 13.9% a year earlier, although it slipped from 24.3% in Q1 2026.
• Operating cash burn improved substantially on a sequential basis. Net cash used in operating activities narrowed to $833,000 in Q2 2026 from $6.9 million in Q1 2026 and $6.8 million in Q4 2025. Accounts receivable also declined to $6.2 million from $8.4 million at the end of Q1, which helped working capital.
• Capital investment was relatively limited outside of acquisitions. Purchases of property and equipment were only $28,000 in Q2 2026, compared with $603,000 in Q2 2025. This limits conventional capital spending needs, although the company spent $3.2 million on acquisitions during the quarter.
• Acquisition activity is changing the company’s financial profile. Healthcare Triangle spent $6.0 million on acquisitions in Q1 2026 and another $3.2 million in Q2. Intangible assets increased to $54.8 million, representing roughly 74% of total assets, so investors will need to monitor whether these assets generate the expected revenue and cash flow.
• Financing activity has been central to liquidity management. Q2 included $75.8 million of debt issuance and $74.3 million of debt repayment, producing approximately $1.5 million of net debt financing. The company also issued $537,000 of common equity. The large gross debt transactions may reflect refinancing or restructuring rather than a comparable increase in borrowings.
• Reported share counts and earnings data are difficult to compare. Weighted-average basic shares rose to 2.8 million in Q2 2026 from 931,000 in Q1, while prior quarters show extreme volatility. Restatements and unusual share-count changes make per-share trends less reliable without reviewing the company’s filings for reverse splits, conversions and other capital-structure transactions.
• The company remains deeply unprofitable. Q2 2026 operating loss was $4.1 million, compared with a $3.6 million loss in Q1. Consolidated net loss was approximately $4.4 million, and net loss attributable to common shareholders was $4.2 million, or $1.56 per diluted share.
• Operating expenses continue to exceed gross profit by a wide margin. Selling, general and administrative expense increased to $4.8 million in Q2 2026, while marketing expense was $720,000. Together, these expenses consumed far more than the company’s $2.1 million of gross profit, preventing meaningful operating leverage despite the revenue rebound.
• Liquidity and balance-sheet risk remain significant. Cash fell to $1.9 million from $4.3 million at the end of Q1, while total current liabilities were $16.0 million versus $9.6 million of current assets. Total debt was approximately $11.8 million, and retained earnings were negative $53.5 million. The company may need continued financing, stronger collections and sustained revenue growth to support operations.

Overall, the latest statements contain a few encouraging signs: revenue is materially higher than a year ago, gross margins have improved and operating cash outflows have narrowed. However, Healthcare Triangle has not yet demonstrated a sustainable path to profitability or positive recurring cash flow. The substantial reliance on acquisitions, debt activity and equity issuance—combined with a weak current ratio and a balance sheet dominated by intangible assets—keeps the stock’s financial risk elevated.

Investors should also use caution when comparing periods because several 2024 and 2025 figures are identified as restated, and some Q1 2026 income-statement lines do not reconcile cleanly with consolidated net income. The company’s future outlook will depend heavily on whether the recent revenue growth can continue while management reduces operating expenses and converts sales into cash.